Bronchial Asthma Clinical Trial
Official title:
Preventive and Personalized Medicine (2021-2023)
NCT number | NCT05088512 |
Other study ID # | 1207 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 23, 2021 |
Est. completion date | January 20, 2023 |
Verified date | March 2023 |
Source | Asfendiyarov Kazakh National Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
To research for a genetic marker of bronchial asthma, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with bronchial asthma and normal control will be performed.
Status | Completed |
Enrollment | 300 |
Est. completion date | January 20, 2023 |
Est. primary completion date | January 20, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 65 Years |
Eligibility | Inclusion Criteria: - Persons with bronchial asthma confirmed by a doctor; - The age of the patients is from 5 to 60 years; - Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs. - Persons who are able and willing to provide written informed consent; - Persons capable and willing to comply with the research protocol; Exclusion Criteria: - Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent; - Pregnant or lactating women; - Tuberculosis of any localization in the active phase and in history; - Severe and decompensated diseases of the liver and kidneys, cardiovascular system; - Severe and decompensated course of endocrine diseases; - Autoimmune diseases; - Systemic diseases; - Oncological diseases; |
Country | Name | City | State |
---|---|---|---|
Kazakhstan | Kazakhstan | Almaty |
Lead Sponsor | Collaborator |
---|---|
Asfendiyarov Kazakh National Medical University |
Kazakhstan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of SNPs associated with bronchial asthma | Using SNPsto identify candidate genes associate with bronchial asthma | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02934945 -
Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients
|
Phase 4 | |
Completed |
NCT02561351 -
Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation
|
N/A | |
Recruiting |
NCT01759472 -
Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test
|
N/A | |
Completed |
NCT01918293 -
Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult
|
N/A | |
Completed |
NCT01203904 -
Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation
|
N/A | |
Completed |
NCT00536731 -
Symbicort Rapihaler Therapeutic Equivalence Study
|
Phase 3 | |
Completed |
NCT01762917 -
Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing
|
N/A | |
Completed |
NCT00331929 -
Respiratory Health Study of Children in Kiryat Tivon
|
N/A | |
Completed |
NCT00930826 -
Childhood Asthma and Schooling: The Truth Unveiled
|
N/A | |
Completed |
NCT00327028 -
Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma
|
Phase 4 | |
Completed |
NCT00413387 -
Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)
|
Phase 3 | |
Completed |
NCT00153283 -
Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma
|
Phase 4 | |
Completed |
NCT00950794 -
Study of Salmeterol (SN408D) for Adult Asthma
|
Phase 4 | |
Completed |
NCT00142025 -
Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma
|
Phase 4 | |
Completed |
NCT00153270 -
Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma
|
Phase 4 | |
Completed |
NCT03450434 -
XC8 in the Treatment of Patients With Bronchial Asthma
|
Phase 2 | |
Recruiting |
NCT05189613 -
Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis
|
N/A | |
Recruiting |
NCT04128111 -
Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
|
||
Completed |
NCT06326632 -
Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma
|
N/A | |
Completed |
NCT01232322 -
Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation
|
N/A |